Imagine a surgeon trying to find a tiny piece of bad tissue in a large area, but it all looks the same color. This technology acts like a pair of high-tech glasses that highlights the cancer in different colors in real-time. It removes the guesswork, making it much easier to see exactly what needs to be removed during surgery.
Surgeons struggle to distinguish cancerous tissue from healthy tissue during endoscopy due to poor visual contrast and no tactile feedback. This leads to high false-negative rates and costly cancer recurrences.
The rMSI 2 prototype, a real-time multi-spectral imaging platform that provides multi-parametric images for tissue differentiation.
If you are an equipment manufacturer dealing with the limitation that current systems only offer one visualization capability — this project developed the rMSI platform that provides multi-parametric images. This allows a single device to replace multiple specialized tools, reducing procurement costs for hospitals.
If you are a clinic dealing with high cancer recurrence rates and the cost of repeated surgeries — this project developed a real-time imaging tool that reduces false negatives, which can be as high as 20% in bladder cancer. This leads to better patient outcomes and fewer repeat hospital visits.
If you are an insurer dealing with the economic strain of 300,000 annual bladder cancer relapses in the EU and US — this project developed a precision detection tool that reduces disease progression. This lowers the long-term cost of treating chronic relapses and repeated surgical interventions.
Based on available project data, specific unit pricing is not disclosed, but the project aims to reduce the high procurement and maintenance costs hospitals currently face by replacing multiple single-purpose devices with one platform.
The company has developed a prototype (rMSI 2) and is currently seeking funding to complete clinical pilots and CE certification for a market launch in 2024.
Based on available project data, the technology is being developed by Thericon GmbH, but specific patent or licensing terms are not provided.
The project is currently working toward achieving CE certification and completing safety tests to allow for legal market entry.
The project objective explicitly targets a market launch in 2024.
The project is led by a single SME, Thericon GmbH from Germany. With a 100% industry ratio and no university or research partners, the project is heavily focused on commercialization and productization rather than basic research, as evidenced by the goal of CE certification.
Contact Thericon GmbH in Germany regarding rMSI 2 clinical pilots.
Contact us to explore licensing or partnership opportunities with Thericon GmbH.
